S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:NBTX

Nanobiotix Stock Forecast, Price & News

$8.98
0.00 (0.00%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.98
$8.98
50-Day Range
$7.13
$9.85
52-Week Range
$6.51
$20.00
Volume
39 shs
Average Volume
6,653 shs
Market Capitalization
$312.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive NBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.


Nanobiotix logo

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBTX
Phone
N/A
Fax
N/A
Employees
89
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.87 million
Book Value
$2.41 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$312.74 million
Optionable
Not Optionable

Company Calendar

Today
1/22/2022
Next Earnings (Estimated)
3/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.80 out of 5 stars

Medical Sector

1334th out of 1,418 stocks

Pharmaceutical Preparations Industry

652nd out of 684 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Nanobiotix (NASDAQ:NBTX) Frequently Asked Questions

Is Nanobiotix a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nanobiotix stock.
View analyst ratings for Nanobiotix
or view top-rated stocks.

Are investors shorting Nanobiotix?

Nanobiotix saw a drop in short interest in December. As of December 15th, there was short interest totaling 1,200 shares, a drop of 58.6% from the November 30th total of 2,900 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is presently 0.3 days.
View Nanobiotix's Short Interest
.

When is Nanobiotix's next earnings date?

Nanobiotix is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Nanobiotix
.

Who are Nanobiotix's key executives?

Nanobiotix's management team includes the following people:
  • Mr. Laurent Levy, Co-Founder, Pres of the Exec. Board & CEO (Age 48, Pay $612.35k)
  • Ms. Anne-Juliette Hermant M.A., Chief People Officer & Member of Exec. Board (Age 47, Pay $358.08k)
  • Prof. Para Prasad Ph.D., Co-Founder and Member of Scientific Board (Age 76)
  • Mr. Earl J. Bergey Ph.d., Co-Founder (Age 66)
  • Mr. Bart Van Rhijn, CFO & Member of Exec. Board
  • Mr. Alain Dostie, Chief Operating Officer
  • Ms. Kathryn M. McNeil, Sr. VP of Investor Relations (Age 46)
  • Mr. Brandon Owens, VP of Strategic Marketing & Corp. Communication
  • Ms. Elsa Borghi, Head of Innovation & Drug Discovery
  • Ms. Sarah Gaubert, Head of Communication & Public Affairs Department

When did Nanobiotix IPO?

(NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.

What is Nanobiotix's stock symbol?

Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX."

How do I buy shares of Nanobiotix?

Shares of NBTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nanobiotix's stock price today?

One share of NBTX stock can currently be purchased for approximately $8.98.

How much money does Nanobiotix make?

Nanobiotix has a market capitalization of $312.74 million and generates $2.87 million in revenue each year.

How many employees does Nanobiotix have?

Nanobiotix employs 89 workers across the globe.

What is Nanobiotix's official website?

The official website for Nanobiotix is www.nanobiotix.com.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.